EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication

Pablo Tebas, Julie K Jadlowsky, Pamela A Shaw, Lifeng Tian, Erin Esparza, Andrea L Brennan, Sukyung Kim, Soe Yu Naing, Max W Richardson, Ashley N Vogel, Colby R Maldini, Hong Kong und 14 weitere

Journal of Clinical Investigation · 01.04.2021 · 131 (7)

DOI: 10.1172/jci144486 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.04.2021. Verfasst von Pablo Tebas und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, Gene Editing, HIV Infections, Lymphocyte Transfusion. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIAID, Sangamo Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD4-Positive T-LymphocytesGene EditingHIV InfectionsLymphocyte TransfusionReceptors, CCR5AdultAnti-Retroviral AgentsCD8-Positive T-LymphocytesFemaleHIV-1HumansMaleMiddle AgedViral LoadVirus Replication

Stichwörter der Autor:innen

AIDS/HIVGene therapyT cells

Substanzen

Anti-Retroviral AgentsCCR5 protein, humanReceptors, CCR5

Autor:innen und Institutionen

  • Department of Medicine.
  • Department of Microbiology and Center for Cellular Immunotherapies.
  • Department of Biostatistics, Epidemiology and Informatics, and.
  • Department of Pathology and Laboratory Medicine and Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Sangamo Therapeutics Inc., Richmond, California, USA.

Förderung

  • NIAID NIH HHS
  • NIAID
  • Sangamo Therapeutics

Zitieren

APA

Tebas, P., Jadlowsky, J. K., Shaw, P. A., Tian, L., Esparza, E., Brennan, A. L., Kim, S., Naing, S. Y., Richardson, M. W., Vogel, A. N., Maldini, C. R., Kong, H., Liu, X., Lacey, S. F., Bauer, A. M., Mampe, F., Richman, L. P., Lee, G., Ando, D., …, & Riley, J. L. (2021). CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. Journal of Clinical Investigation, 131(7). https://doi.org/10.1172/jci144486

Vancouver

Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, et al. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. Journal of Clinical Investigation. 2021;131(7). doi:10.1172/jci144486

BibTeX
@article{Tebas2021,
  author = {Tebas, Pablo and Jadlowsky, Julie K and Shaw, Pamela A and Tian, Lifeng and Esparza, Erin and Brennan, Andrea L and Kim, Sukyung and Naing, Soe Yu and Richardson, Max W and Vogel, Ashley N and Maldini, Colby R and Kong, Hong and Liu, Xiaojun and Lacey, Simon F and Bauer, Anya M and Mampe, Felicity and Richman, Lee P and Lee, Gary and Ando, Dale and Levine, Bruce L and Porter, David L and Zhao, Yangbing and Siegel, Don L and Bar, Katharine J and June, Carl H and Riley, James L},
  title = {CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication},
  journal = {Journal of Clinical Investigation},
  year = {2021},
  volume = {131},
  number = {7},
  doi = {10.1172/jci144486}
}
Kostenlos starten →